BioNeutral Laboratories Announces the Appointment of Stephen Browand as a Director to Head Military, Homeland Security and Government...(deBioNeutralizers and ChemoNeutralizers....)
Navigation Links
| HOME >> BIOLOGY >> TECHNOLOGY |
BioNeutral Laboratories Announces the Appointment of Stephen Browand as a Director to Head Military, Homeland Security and Governmental Affairs
Date:6/25/2008
de BioNeutralizers and ChemoNeutralizers. BioNeutralizers disinfect, decontaminate and sterilize. BioNeutral believes it has the broadest-based, fastest-acting, most effective and safest antimicrobial known. This class of products has important applications for consumers, healthcare and the military. ChemoNeutralizers irreversibly bind chemical contaminant and toxin molecules and render them harmless. Product applications include industrial pollution and protection against chemical weapons of mass destruction.
About Dr. Philip Tierno
Dr. Tierno is a consultant to BioNeutral. He is the Director of
Clinical Microbiology and Diagnostic Immunology at Tisch Hospital, New York
University Medical Center. He is also an Associate Professor at the New
York University School of Medicine, NYU College of Dentistry and SUNY
School of Optometry in New York City. Dr. Tierno is a member of the NYC
Mayor's MRC (Medical Reserve Corps) and a former member of New York City's
task force on bioterrorism. Dr. Tierno's work in the field of microbiology
has resulted in numerous articles and texts that have been published in
medical and scientific journals. He is co-editor and author of several
books on microbes and biological protection.
Contact:
Stephen J. Browand
Director
Governmental Affairs
Dr. Philip Tierno
Consultant
This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.
'/>"/>
| SOURCE BioNeutral Laboratories Corporation Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. BioNeutral Announces a BREAKTHROUGH in the Fight Against Bioterrorism
2. ARUP Laboratories ARUP Consult(R) Recognized as a Computerworld Honors Program Laureate
3. Frontage Laboratories Completes Acquisition of Advanced Biomedical Research, Inc. (ABR)
4. Barrier Therapeutics to Merge Into Stiefel Laboratories
5. ARUP Laboratories Partners With Pathology Service Associates
6. Fontus Pharmaceuticals Acquires Nephrology and Endocrinology Drug from Roche Laboratories Inc.
7. Cato Research and Neuland Laboratories Form Cato Research Neuland India, Ltd.
8. Forest Laboratories, Inc. and Laboratorios Almirall, S.A. to Host Webcast to Discuss Aclidinium Bromide Data Presentations at the American Thoracic Society Annual Congress
9. Forest Laboratories, Inc. and Daiichi Sankyo, Inc. Announce the Termination of the AZOR Co-Promotion Agreement
10. IDEXX Laboratories Announces First Quarter Results
11. ARUP Laboratories CEO and Co-Founder Announces Retirement
Post Your Comments:
Breaking Biology Technology:Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 2Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 4Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 5Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 6Sirius Genomics Announces Change in Leadership 2Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 2Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 3Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 4AEterna Zentaris Announces Appointment of New Board Member 2
[0] Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain[0] Sirius Genomics Announces Change in Leadership[0] Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea[0] AEterna Zentaris Announces Appointment of New Board Member
Other Biology Technology:GenVault Partnership with Genome Quebec Brings $3.3 Million Sale of Dynamic Archive Product 2GenVault Partnership with Genome Quebec Brings $3.3 Million Sale of Dynamic Archive Product 3GenVault Partnership with Genome Quebec Brings $3.3 Million Sale of Dynamic Archive Product 4Arpida Interim Results for six Months to 30 June 2007 2Arpida Interim Results for six Months to 30 June 2007 3Arpida Interim Results for six Months to 30 June 2007 4Arpida Interim Results for six Months to 30 June 2007 5Arpida Interim Results for six Months to 30 June 2007 6Arpida Interim Results for six Months to 30 June 2007 7Arpida Interim Results for six Months to 30 June 2007 8Arpida Interim Results for six Months to 30 June 2007 9Arpida Interim Results for six Months to 30 June 2007 10Processing Fees on ADRs to be Waived for two Months 2Processing Fees on ADRs to be Waived for two Months 3
Breaking Biology News(10 mins):Potential new heart attack biomarker uncovered 2From fruit fly wings to heart failure -- why Not(ch)? 2ESHRE announces its campus workshop: 'Artificial Insemination: An Update' 2APAC Sensors Market Likely to be Driven by Medical and Process Industries in 2009 Says Frost 26 Sullivan 50833 1APAC Sensors Market Likely to be Driven by Medical and Process Industries in 2009 Says Frost 26 Sullivan 50833 2APAC Sensors Market Likely to be Driven by Medical and Process Industries in 2009 Says Frost 26 Sullivan 50833 3Your own private global warming 9125 1Nano measurement in the third dimension 12903 1Nano measurement in the third dimension 12903 2
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |